Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 3
2009 2
2010 3
2011 3
2012 6
2013 2
2014 5
2015 3
2016 11
2017 10
2018 15
2019 16
2020 21
2021 23
2022 50
2023 16
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 34413145

158 results

Results by year

Filters applied: . Clear all
Page 1
CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody.
Farwell MD, Gamache RF, Babazada H, Hellmann MD, Harding JJ, Korn R, Mascioni A, Le W, Wilson I, Gordon MS, Wu AM, Ulaner GA, Wolchok JD, Postow MA, Pandit-Taskar N. Farwell MD, et al. J Nucl Med. 2022 May;63(5):720-726. doi: 10.2967/jnumed.121.262485. Epub 2021 Aug 19. J Nucl Med. 2022. PMID: 34413145 Free PMC article. Clinical Trial.
First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting.
Pandit-Taskar N, Postow MA, Hellmann MD, Harding JJ, Barker CA, O'Donoghue JA, Ziolkowska M, Ruan S, Lyashchenko SK, Tsai F, Farwell M, Mitchell TC, Korn R, Le W, Lewis JS, Weber WA, Behera D, Wilson I, Gordon M, Wu AM, Wolchok JD. Pandit-Taskar N, et al. J Nucl Med. 2020 Apr;61(4):512-519. doi: 10.2967/jnumed.119.229781. Epub 2019 Oct 4. J Nucl Med. 2020. PMID: 31586002 Free PMC article. Clinical Trial.
Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy.
Maresca KP, Chen J, Mathur D, Giddabasappa A, Root A, Narula J, King L, Schaer D, Golas J, Kobylarz K, Rosfjord E, Keliher E, Chen L, Ram S, Pickering EH, Hardwick JS, Rejto PA, Hussein A, Ilovich O, Staton K, Wilson I, McCarthy TJ. Maresca KP, et al. Mol Imaging Biol. 2021 Dec;23(6):941-951. doi: 10.1007/s11307-021-01621-0. Epub 2021 Jun 18. Mol Imaging Biol. 2021. PMID: 34143379 Free PMC article.
The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment.
Griessinger CM, Olafsen T, Mascioni A, Jiang ZK, Zamilpa C, Jia F, Torgov M, Romero JM, Marchioni F, Satpayev D, Lee C, Zhang G, Nayak TK, Pincha M, Amann M, Mohan PLB, Richard M, Nicolini VG, Sam J, Claus C, Ferrara C, Brünker P, Bacac M, Umana P, Rüttinger D, Wilson IA, Gudas J, Klein C, Tessier JJL. Griessinger CM, et al. Cancer Res. 2020 Jul 1;80(13):2903-2913. doi: 10.1158/0008-5472.CAN-19-3269. Epub 2020 May 14. Cancer Res. 2020. PMID: 32409308
Immuno-PET imaging of tumor endothelial marker 8 (TEM8).
Kuo F, Histed S, Xu B, Bhadrasetty V, Szajek LP, Williams MR, Wong K, Wu H, Lane K, Coble V, Vasalatiy O, Griffiths GL, Paik CH, Elbuluk O, Szot C, Chaudhary A, St Croix B, Choyke P, Jagoda EM. Kuo F, et al. Mol Pharm. 2014 Nov 3;11(11):3996-4006. doi: 10.1021/mp500056d. Epub 2014 Jul 11. Mol Pharm. 2014. PMID: 24984190 Free PMC article.
158 results